This Baby Biotech Has Lots of Running Room, Thanks to This Upcoming “Super” Drug

Original post

I first unveiled this “baby biotech” to my Private Briefing subscribers in our very first publication.

And it’s been a huge winner for them since then.

Your “win” was extended by a big day last Wednesday when bullish news about a drug this company is working on with partner Gilead Sciences Inc. (NASDAQ: GILD) shot our stock up 16.5%.

In short, the stock I’m showing you today is a proverbial “10-Bagger” – the Holy Grail of stock picking. Heck, it almost became a “13-Bagger.”

This is actually the third “10-Bagger” we’ve brought you in the seven years we’ve been blessed to be your market guide.

So let’s take a look…

Join the conversation. Click here to jump to comments…